US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLIMB BIO INC

5.63

-0.0100-0.18%

Post-market: 5.740.1100+1.95%19:46 EST

Volume:700.92K

Turnover:3.95M

Market Cap:268.80M

PE:-7.50

High:5.86

Open:5.58

Low:5.50

Close:5.64

52wk High:6.22

52wk Low:1.05

Shares:47.74M

Float Shares:30.75M

Volume Ratio:1.30

T/O Rate:2.28%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7507

EPS(LYR):-1.5343

ROE:-25.65%

ROA:-17.35%

PB:1.52

PE(LYR):-3.67

Loading ...

Overview Company News Filings

Climb Bio Director Thomas Stephen Basil Reports Disposal of Common Shares

Piper Sandler Initiates Climb Bio at Overweight With $23 Price Target

MT Newswires Live

Climb Bio Initiated at Overweight by Piper Sandler

U.S. RESEARCH ROUNDUP-Applied Materials, Humana, Waste Connections

Climb Bio Inc. to Participate in Major Healthcare Investor Conferences

Ten new option listings and two option delistings on January 22nd

Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM) and Halozyme (HALO)

Climb Bio Inc. Outlines 2026 Strategy With Multiple Clinical Trial Readouts, Expanded Pipeline in Immune-Mediated Diseases, and Financial Guidance Extending Operations Into 2028

Climb Bio Inc. Expands Leadership Team and Board with Key Appointments

Climb Bio Reports Progress in Clinical Trials for Budoprutug and CLYM116

Climb Bio Inc: First Patients Dosed in Budoprutug Prismn Phase 2 Trial in Pmn, With Initial Data Expected Second Half 2026

THOMSON REUTERS

Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026

THOMSON REUTERS

Climb Bio Inc - Cash Runway Expected Into 2028

THOMSON REUTERS

RA Capital Management Reports Acquisition of Climb Bio Inc. Common Shares

BRIEF-Climb Bio Files Complaint Against Alumis And Acelyrin - SEC Filing

Climb Bio Inc - Files Complaint Against Alumis and ACELYRIN - SEC Filing

THOMSON REUTERS

Climb Bio Inc - Complaint Seeks Declaratory Judgment That Co's Budoprutug Drug Candidate Is Not "Product" Under Apa

THOMSON REUTERS

Climb Bio Inc - Does Not Owe a Milestone Payment Sought by Alumis in Connection With Its Development of Budoprutug

THOMSON REUTERS

Climb Bio Inc - Complaint Relating to a Dispute Concerning an Asset Purchase Agreement, Dated as of January 11, 2024

THOMSON REUTERS

Climb Bio Sues Alumis Over $3 Million Milestone Dispute

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CLYM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CLYM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLYM\",,,,,undefined,":{"symbol":"CLYM","market":"US","secType":"STK","nameCN":"CLIMB BIO INC","latestPrice":5.63,"timestamp":1771621200000,"preClose":5.64,"halted":0,"volume":700917,"hourTrading":{"tag":"盘后","latestPrice":5.74,"preClose":5.63,"latestTime":"19:46 EST","volume":170529,"amount":960105.3874,"timestamp":1771634772947,"change":0.11,"changeRate":0.019538,"amplitude":0.019538},"delay":0,"changeRate":-0.0017730496453900331,"floatShares":30748027,"shares":47744400,"eps":-0.75067,"marketStatus":"Market Closed","change":-0.01,"latestTime":"02-20 16:00:00 EST","open":5.58,"high":5.86,"low":5.5,"amount":3949406.7641511,"amplitude":0.06383,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.75067,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"listingDate":1628222400000,"exchange":"NASDAQ","adjPreClose":5.64,"preHourTrading":{"tag":"盘前","latestPrice":5.58,"preClose":5.64,"latestTime":"09:29 EST","volume":1,"amount":5.58,"timestamp":1771597799914,"change":-0.06,"changeRate":-0.010638,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":5.74,"preClose":5.63,"latestTime":"19:46 EST","volume":170529,"amount":960105.3874,"timestamp":1771634772947,"change":0.11,"changeRate":0.019538,"amplitude":0.019538},"volumeRatio":1.297577,"impliedVol":4.4395,"impliedVolPercentile":0.7619},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLYM\",,,,,undefined,":{"symbol":"CLYM","floatShares":30748027,"roa":"-17.35%","roe":"-25.65%","lyrEps":-1.5343,"volumeRatio":1.297577,"shares":47744400,"dividePrice":0,"high":5.86,"amplitude":0.06383,"preClose":5.64,"low":5.5,"week52Low":1.05,"pbRate":"1.52","week52High":6.2199,"institutionHeld":0,"latestPrice":5.63,"eps":-0.75067,"divideRate":0,"volume":700917,"delay":0,"ttmEps":-0.75067,"open":5.58,"prevYearClose":4,"prevWeekClose":5.67,"prevMonthClose":4.47,"prevQuarterClose":4,"fiveDayClose":5.27,"twentyDayClose":4.91,"sixtyDayClose":1.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLYM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"CLYM","fiscalQuarterEnding":"2025/09","expectedEps":-0.16,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-0.19},{"market":"US","date":"2025-08-12","symbol":"CLYM","fiscalQuarterEnding":"2025/06","expectedEps":-0.19,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.13},{"market":"US","date":"2021-09-13","symbol":"CLYM","fiscalQuarterEnding":"2021/06","expectedEps":-2.3,"name":null,"time":"","type":"earning","dateTimestamp":1631505600000,"reportTimeType":"","actualEps":-3.11}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLYM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLYM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.625,"buy":0.375,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.625,"analysts":8,"updateTime":1771045200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CLYM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CLYM","date":"2026-02-19","current":-7.499967,"percent":0.061404,"low":-6.583195,"twenty":-3.637653,"median":-2.391265,"eighty":-1.136908,"high":-0.85032,"avg":-2.524734,"sd":1.406893,"marketCap":262594392},"quantilePoints":[{"date":"2024-10-04","current":-5.327624,"twenty":-5.327624,"median":-5.327624,"eighty":-5.327624,"marketCap":342006831},{"date":"2024-10-11","current":-5.369409,"twenty":-5.463426,"median":-5.390302,"eighty":-5.369409,"marketCap":344689237},{"date":"2024-10-18","current":-5.076912,"twenty":-5.494765,"median":-5.390302,"eighty":-5.327624,"marketCap":325912392},{"date":"2024-10-25","current":-4.85754,"twenty":-5.463426,"median":-5.327624,"eighty":-5.014234,"marketCap":311829757},{"date":"2024-10-31","current":-4.094958,"twenty":-5.404927,"median":-5.238831,"eighty":-4.776059,"marketCap":262875838},{"date":"2024-11-08","current":-3.677105,"twenty":-5.390302,"median":-5.014234,"eighty":-4.074065,"marketCap":236051773},{"date":"2024-11-15","current":-3.107258,"twenty":-5.373588,"median":-4.888879,"eighty":-3.806639,"marketCap":214779913},{"date":"2024-11-22","current":-2.917613,"twenty":-5.335981,"median":-4.293438,"eighty":-3.619939,"marketCap":201671280},{"date":"2024-11-29","current":-3.141297,"twenty":-5.327624,"median":-4.220314,"eighty":-3.127681,"marketCap":217132744},{"date":"2024-12-06","current":-2.830085,"twenty":-5.277482,"median":-3.974826,"eighty":-3.040153,"marketCap":195621141},{"date":"2024-12-13","current":-2.742557,"twenty":-5.237786,"median":-3.781569,"eighty":-2.995417,"marketCap":189571003},{"date":"2024-12-20","current":-1.896449,"twenty":-5.13959,"median":-3.671882,"eighty":-2.96235,"marketCap":131086332},{"date":"2024-12-27","current":-2.207661,"twenty":-5.051841,"median":-3.301766,"eighty":-2.921503,"marketCap":152597935},{"date":"2025-01-03","current":-2.013153,"twenty":-5.003788,"median":-3.151022,"eighty":-2.57139,"marketCap":139153183},{"date":"2025-01-10","current":-1.818646,"twenty":-4.962003,"median":-3.124277,"eighty":-2.236837,"marketCap":125708431},{"date":"2025-01-17","current":-1.954801,"twenty":-4.920218,"median":-3.063494,"eighty":-2.032604,"marketCap":135119757},{"date":"2025-01-24","current":-1.770019,"twenty":-4.870076,"median":-3.005142,"eighty":-1.952856,"marketCap":122347243},{"date":"2025-01-31","current":-1.876998,"twenty":-4.531614,"median":-2.995417,"eighty":-1.91979,"marketCap":129741856},{"date":"2025-02-07","current":-1.701941,"twenty":-4.324777,"median":-2.96624,"eighty":-1.892559,"marketCap":117641580},{"date":"2025-02-14","current":-1.546335,"twenty":-4.251653,"median":-2.932201,"eighty":-1.865328,"marketCap":106885778},{"date":"2025-02-21","current":-1.400454,"twenty":-4.228671,"median":-2.873849,"eighty":-1.840042,"marketCap":96802214},{"date":"2025-02-28","current":-1.351828,"twenty":-4.1451,"median":-2.528598,"eighty":-1.818646,"marketCap":93441026},{"date":"2025-03-07","current":-1.429631,"twenty":-4.03228,"median":-2.256288,"eighty":-1.756403,"marketCap":98818927},{"date":"2025-03-14","current":-1.293475,"twenty":-3.971692,"median":-2.18821,"eighty":-1.542445,"marketCap":89407600},{"date":"2025-03-21","current":-1.244848,"twenty":-3.871407,"median":-2.022879,"eighty":-1.474368,"marketCap":86046412},{"date":"2025-03-28","current":-1.159638,"twenty":-3.794104,"median":-1.954801,"eighty":-1.429631,"marketCap":85693751},{"date":"2025-04-04","current":-1.050066,"twenty":-3.724618,"median":-1.940213,"eighty":-1.381004,"marketCap":77596704},{"date":"2025-04-11","current":-1.059197,"twenty":-3.680923,"median":-1.925625,"eighty":-1.357663,"marketCap":78271458},{"date":"2025-04-17","current":-1.150507,"twenty":-3.672927,"median":-1.896449,"eighty":-1.324596,"marketCap":85018997},{"date":"2025-04-25","current":-1.187031,"twenty":-3.573219,"median":-1.876998,"eighty":-1.28764,"marketCap":87718013},{"date":"2025-05-02","current":-1.150507,"twenty":-3.328025,"median":-1.867273,"eighty":-1.252628,"marketCap":85018997},{"date":"2025-05-09","current":-1.088206,"twenty":-3.166583,"median":-1.847822,"eighty":-1.218825,"marketCap":80415162},{"date":"2025-05-16","current":-0.872124,"twenty":-3.152968,"median":-1.818646,"eighty":-1.187031,"marketCap":81090920},{"date":"2025-05-23","current":-0.872124,"twenty":-3.141297,"median":-1.818646,"eighty":-1.164325,"marketCap":81090920},{"date":"2025-05-30","current":-0.886659,"twenty":-3.134489,"median":-1.784607,"eighty":-1.159638,"marketCap":82442435},{"date":"2025-06-06","current":-0.901194,"twenty":-3.10434,"median":-1.750568,"eighty":-1.150507,"marketCap":83793951},{"date":"2025-06-13","current":-0.930265,"twenty":-3.086835,"median":-1.590099,"eighty":-1.125277,"marketCap":86496981},{"date":"2025-06-20","current":-0.893927,"twenty":-3.063494,"median":-1.522022,"eighty":-1.106495,"marketCap":83118193},{"date":"2025-06-27","current":-0.91573,"twenty":-3.014867,"median":-1.478258,"eighty":-1.095721,"marketCap":85145466},{"date":"2025-07-03","current":-0.930265,"twenty":-3.007087,"median":-1.439356,"eighty":-1.066502,"marketCap":86496981},{"date":"2025-07-11","current":-0.981139,"twenty":-2.997362,"median":-1.429631,"eighty":-1.007303,"marketCap":91227285},{"date":"2025-07-18","current":-1.061084,"twenty":-2.995417,"median":-1.400454,"eighty":-0.995674,"marketCap":98660619},{"date":"2025-07-25","current":-1.075619,"twenty":-2.995417,"median":-1.376141,"eighty":-1.007303,"marketCap":100012135},{"date":"2025-08-01","current":-1.017477,"twenty":-2.979856,"median":-1.361553,"eighty":-1.016024,"marketCap":94606073},{"date":"2025-08-08","current":-1.220973,"twenty":-2.968185,"median":-1.346965,"eighty":-1.017477,"marketCap":113527288},{"date":"2025-08-15","current":-2.492713,"twenty":-2.95846,"median":-1.351828,"eighty":-1.023291,"marketCap":116554252},{"date":"2025-08-22","current":-3.173861,"twenty":-2.979856,"median":-1.366416,"eighty":-1.024745,"marketCap":148403379},{"date":"2025-08-29","current":-3.333278,"twenty":-3.007087,"median":-1.381004,"eighty":-1.030392,"marketCap":155857430},{"date":"2025-09-05","current":-3.376756,"twenty":-3.075164,"median":-1.400454,"eighty":-1.031929,"marketCap":157890353},{"date":"2025-09-12","current":-3.478204,"twenty":-3.149077,"median":-1.429631,"eighty":-1.042845,"marketCap":162633840},{"date":"2025-09-19","current":-3.246323,"twenty":-3.164638,"median":-1.439356,"eighty":-1.052316,"marketCap":151791584},{"date":"2025-09-26","current":-3.043428,"twenty":-3.197049,"median":-1.483121,"eighty":-1.053816,"marketCap":142304610},{"date":"2025-10-03","current":-2.956473,"twenty":-3.173861,"median":-1.53661,"eighty":-1.057045,"marketCap":138238764},{"date":"2025-10-10","current":-2.739085,"twenty":-3.171828,"median":-1.667902,"eighty":-1.060329,"marketCap":128074149},{"date":"2025-10-17","current":-2.82604,"twenty":-3.164638,"median":-1.760293,"eighty":-1.06543,"marketCap":132139995},{"date":"2025-10-24","current":-2.88401,"twenty":-3.171828,"median":-1.808921,"eighty":-1.072703,"marketCap":134850559},{"date":"2025-10-31","current":-2.88401,"twenty":-3.164638,"median":-1.818646,"eighty":-1.075619,"marketCap":134850559},{"date":"2025-11-07","current":-2.603692,"twenty":-3.149077,"median":-1.838097,"eighty":-1.083171,"marketCap":132139995},{"date":"2025-11-14","current":-2.512362,"twenty":-3.141297,"median":-1.857547,"eighty":-1.088206,"marketCap":127504893},{"date":"2025-11-21","current":-2.324271,"twenty":-3.120874,"median":-1.876998,"eighty":-1.092715,"marketCap":117959072},{"date":"2025-11-28","current":-2.539232,"twenty":-3.101423,"median":-1.886723,"eighty":-1.096373,"marketCap":128868582},{"date":"2025-12-05","current":-2.324271,"twenty":-3.090364,"median":-1.896449,"eighty":-1.097379,"marketCap":117959072},{"date":"2025-12-12","current":-3.090071,"twenty":-3.088805,"median":-1.930487,"eighty":-1.097422,"marketCap":156824200},{"date":"2025-12-19","current":-5.88457,"twenty":-3.141297,"median":-1.945076,"eighty":-1.098568,"marketCap":298647825},{"date":"2025-12-26","current":-4.562679,"twenty":-3.173183,"median":-1.969389,"eighty":-1.101167,"marketCap":231560509},{"date":"2026-01-02","current":-3.763034,"twenty":-3.231831,"median":-2.032604,"eighty":-1.10469,"marketCap":190977740},{"date":"2026-01-09","current":-4.308674,"twenty":-3.260816,"median":-2.195782,"eighty":-1.104852,"marketCap":218669512},{"date":"2026-01-16","current":-3.54666,"twenty":-3.333278,"median":-2.236837,"eighty":-1.106495,"marketCap":179996519},{"date":"2026-01-23","current":-4.619124,"twenty":-3.365162,"median":-2.283966,"eighty":-1.112485,"marketCap":234425175},{"date":"2026-01-30","current":-4.496826,"twenty":-3.449218,"median":-2.324271,"eighty":-1.121288,"marketCap":228218399},{"date":"2026-02-06","current":-4.374527,"twenty":-3.488132,"median":-2.337706,"eighty":-1.123114,"marketCap":222011622},{"date":"2026-02-13","current":-4.957797,"twenty":-3.580579,"median":-2.363428,"eighty":-1.131766,"marketCap":251613172},{"date":"2026-02-19","current":-5.174172,"twenty":-3.637653,"median":-2.391265,"eighty":-1.136908,"marketCap":262594392}],"updateTime":1771646402553},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CLYM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612460668","title":"Climb Bio Director Thomas Stephen Basil Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2612460668","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612460668?lang=en_us&edition=fundamental","pubTime":"2026-02-18 05:06","pubTimestamp":1771362392,"startTime":"0","endTime":"0","summary":"Thomas Stephen Basil, Director of Climb Bio Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL8cPgVG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Climb Bio Director Thomas Stephen Basil Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CLYM"],"gpt_icon":0},{"id":"2611154911","title":"Piper Sandler Initiates Climb Bio at Overweight With $23 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2611154911","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611154911?lang=en_us&edition=fundamental","pubTime":"2026-02-13 20:36","pubTimestamp":1770986164,"startTime":"0","endTime":"0","summary":"Climb Bio (CLYM) has an average rating of buy and mean price target of $11.43, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CLYM","BK4139","BK4539"],"gpt_icon":0},{"id":"2611813070","title":"Climb Bio Initiated at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2611813070","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611813070?lang=en_us&edition=fundamental","pubTime":"2026-02-13 17:54","pubTimestamp":1770976440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 13, 2026 04:54 ET (09:54 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4539","BK4139"],"gpt_icon":0},{"id":"2611138644","title":"U.S. RESEARCH ROUNDUP-Applied Materials, Humana, Waste Connections","url":"https://stock-news.laohu8.com/highlight/detail?id=2611138644","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611138644?lang=en_us&edition=fundamental","pubTime":"2026-02-13 14:43","pubTimestamp":1770965029,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Applied Materials, Humana, Waste Connections Feb 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nL4N3Z90HT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COIA","BDC","AVNT","CGNX","BFAM","TXG","APP","CLYM","ETR","ALNY","AGIO","BAX","LU1861215975.USD","DLTR","CRSR","ALB","COIO","CW","DKNG","ANET","COIG","CROX","COHR","CONY","EXC","CONI","COYY","BROS","ECL","BIO","AMG","DBD","CBRE","COR","ABNB","CONL","ADI","BRKR","DXCM","AEP","DAR","COIW","FIAT","EEFT","AEE","CONX","BBIO","APPX","COIN","AMAT"],"gpt_icon":1},{"id":"2609741533","title":"Climb Bio Inc. to Participate in Major Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2609741533","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609741533?lang=en_us&edition=fundamental","pubTime":"2026-02-05 20:00","pubTimestamp":1770292844,"startTime":"0","endTime":"0","summary":"Climb Bio Inc. will participate in several upcoming investor conferences, including a fireside chat at Guggenheim's Emerging Outlook: Biotech Summit on Thursday, February 12, 2026, from 3:00 to 3:25 p.m. ET. The company will also attend the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026, from 1:20 to 1:50 p.m. ET, and the Leerink Global Healthcare Conference on Monday, March 9, 2026, from 2:20 to 2:50 p.m. ET. Live webcasts and replays of these events will be available on the Climb Bio website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on February 05, 2026, and is solely responsible for the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL2sMd58:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","IE00B3QW5Z07.USD","LU2095319765.USD","LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4139","SG9999014021.USD","SG9999014039.USD","BK4585","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","BK4539","SG9999014005.SGD","BK4588","IE00BKPKM429.USD","NDAQ"],"gpt_icon":0},{"id":"2605849457","title":"Ten new option listings and two option delistings on January 22nd","url":"https://stock-news.laohu8.com/highlight/detail?id=2605849457","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605849457?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:36","pubTimestamp":1769088965,"startTime":"0","endTime":"0","summary":"New option listings for January 22nd include Aardvark Therapeutics Inc (AARD), Anteris Technologies Global Corp (AVR), Climb Bio Inc (CLYM), REX Dr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ten-new-option-listings-and-two-option-delistings-on-january-22nd-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ten-new-option-listings-and-two-option-delistings-on-january-22nd-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVR","AARD","CLYM","BK4539","BK4082"],"gpt_icon":0},{"id":"2602390675","title":"Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM) and Halozyme (HALO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602390675","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602390675?lang=en_us&edition=fundamental","pubTime":"2026-01-09 04:01","pubTimestamp":1767902477,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Climb Bio (CLYM – Research Report) and Halozyme (HALO – Research ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-climb-bio-clym-and-halozyme-halo-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-climb-bio-clym-and-halozyme-halo-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4585","HCSG","HALO","LABU","LU0053671581.USD","LU0029874061.USD","LU0128526141.USD","BK4588","XBI","BK4137","BK4139","CLYM","BK4539","XLV"],"gpt_icon":0},{"id":"2601036935","title":"Climb Bio Inc. Outlines 2026 Strategy With Multiple Clinical Trial Readouts, Expanded Pipeline in Immune-Mediated Diseases, and Financial Guidance Extending Operations Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2601036935","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601036935?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:08","pubTimestamp":1767874109,"startTime":"0","endTime":"0","summary":"Climb Bio Inc. Outlines 2026 Strategy With Multiple Clinical Trial Readouts, Expanded Pipeline in Immune-Mediated Diseases, and Financial Guidance Extending Operations Into 2028. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL8s7bC9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4539","BK4139"],"gpt_icon":0},{"id":"2601366299","title":"Climb Bio Inc. Expands Leadership Team and Board with Key Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366299","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366299?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:02","pubTimestamp":1767873730,"startTime":"0","endTime":"0","summary":"Climb Bio Inc. has expanded its senior leadership team with the appointments of Edgar D. Charles, M.D., MSc as Chief Medical Officer, Perrin Wilson, Ph.D., as Chief Business Officer, Susan Altschuller, Ph.D., MBA as Chief Financial Officer, Adam Villa, MS, MBA as SVP, Technical Operations, and Ashley Jones as SVP, People & Workforce Strategy. The company also strengthened its Board of Directors with the addition of Kim Cobleigh Drapkin, CPA and Bo Cumbo.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on January 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL81J7rX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","SG9999014013.SGD","BK4539","CLYM","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BKPKM429.USD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4112","BK4139","SG9999014039.USD","LU2210149790.SGD","BK4588","NDAQ","IE00BGHQF748.EUR","LU2095319765.USD"],"gpt_icon":0},{"id":"2601366419","title":"Climb Bio Reports Progress in Clinical Trials for Budoprutug and CLYM116","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366419","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366419?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873647,"startTime":"0","endTime":"0","summary":"Climb Bio Inc. announced significant progress in its clinical development programs, with initial data from key trials expected in the second half of 2026. The company has dosed the first patients in the PrisMN Phase 2 trial of budoprutug, its anti-CD19 monoclonal antibody, for primary membranous nephropathy , and is continuing dosing in Phase 1b/2a trials for immune thrombocytopenia  and Phase 1b in systemic lupus erythematosus . Regulatory clearance was achieved for a SLE trial in China, with the first patient dosing anticipated in the first half of 2026. Additionally, the first subjects have been dosed in the Phase 1 healthy volunteer study of CLYM116, Climb Bio's anti-APRIL monoclonal antibody. Initial research results from these studies have not yet been presented but are expected to be reported in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL9qc6WN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014013.SGD","LU2210150020.SGD","SG9999014039.USD","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014021.USD","BK4539","BK4112","CLYM","BK4588","SG9999014005.SGD","IE00B64PRP62.GBP","LU0314104364.USD","BK4139","NDAQ","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2601366226","title":"Climb Bio Inc: First Patients Dosed in Budoprutug Prismn Phase 2 Trial in Pmn, With Initial Data Expected Second Half 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366226","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366226?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA7SZC2H:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4539","BK4139"],"gpt_icon":0},{"id":"2601366166","title":"Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366166","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366166?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873604,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA7SZC2H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLYM","BK4539"],"gpt_icon":0},{"id":"2601142366","title":"Climb Bio Inc - Cash Runway Expected Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2601142366","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601142366?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA7SZC2H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4139","BK4539"],"gpt_icon":0},{"id":"2601738144","title":"RA Capital Management Reports Acquisition of Climb Bio Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601738144","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601738144?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:56","pubTimestamp":1767822990,"startTime":"0","endTime":"0","summary":"RA Capital Management, L.P. reported the acquisition of common shares of Climb Bio Inc. , according to a recent SEC filing. Other reporting beneficial owners include RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., and RA Capital Nexus Fund II, L.P., among other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL5nMF0y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RA Capital Management Reports Acquisition of Climb Bio Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4139","BK4539"],"gpt_icon":0},{"id":"2600731704","title":"BRIEF-Climb Bio Files Complaint Against Alumis And Acelyrin - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2600731704","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600731704?lang=en_us&edition=fundamental","pubTime":"2026-01-01 06:36","pubTimestamp":1767220603,"startTime":"0","endTime":"0","summary":"BRIEF-Climb Bio Files Complaint Against Alumis And Acelyrin - SEC FilingDec 31  - Climb Bio Inc CLYM.O:CLIMB BIO INC - FILES COMPLAINT AGAINST ALUMIS AND ACELYRIN - SEC FILINGCLIMB BIO INC - COMPLAINT RELATING TO A DISPUTE CONCERNING AN ASSET PURCHASE AGREEMENT, DATED AS OF JANUARY 11, 2024CLIMB BIO INC - COMPLAINT SEEKS DECLARATORY JUDGMENT THAT CO'S BUDOPRUTUG DRUG CANDIDATE IS NOT \"PRODUCT\" UNDER APACLIMB BIO INC - DOES NOT OWE A MILESTONE PAYMENT SOUGHT BY ALUMIS IN CONNECTION WITH ITS DEVELOPMENT OF BUDOPRUTUGSource text: [ID:n0001193125-25-338318]Further company coverage: CLYM.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y106H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4539","BK4139"],"gpt_icon":0},{"id":"2600701810","title":"Climb Bio Inc - Files Complaint Against Alumis and ACELYRIN - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701810","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600701810?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:14","pubTimestamp":1767215642,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y106H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","CLYM"],"gpt_icon":0},{"id":"2600701355","title":"Climb Bio Inc - Complaint Seeks Declaratory Judgment That Co's Budoprutug Drug Candidate Is Not \"Product\" Under Apa","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701355","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600701355?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:14","pubTimestamp":1767215642,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y106H:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","CLYM","BK4139"],"gpt_icon":0},{"id":"2600570133","title":"Climb Bio Inc - Does Not Owe a Milestone Payment Sought by Alumis in Connection With Its Development of Budoprutug","url":"https://stock-news.laohu8.com/highlight/detail?id=2600570133","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600570133?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:14","pubTimestamp":1767215642,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y106H:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","CLYM"],"gpt_icon":0},{"id":"2600018177","title":"Climb Bio Inc - Complaint Relating to a Dispute Concerning an Asset Purchase Agreement, Dated as of January 11, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2600018177","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600018177?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:14","pubTimestamp":1767215642,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y106H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","CLYM"],"gpt_icon":0},{"id":"2600701814","title":"Climb Bio Sues Alumis Over $3 Million Milestone Dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701814","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600701814?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:13","pubTimestamp":1767215610,"startTime":"0","endTime":"0","summary":"Climb Bio Inc., a Massachusetts-based biotechnology company, has filed a lawsuit seeking resolution of a dispute with Alumis Inc. and its subsidiary Acelyrin Inc. The litigation centers on a January 2024 Asset Purchase Agreement, under which Climb acquired assets related to the drug candidate budoprutug. Climb alleges that despite not receiving any royalty-bearing patents from Alumis or Acelyrin, it was invoiced for a $3 million milestone payment after dosing its first patient in a Phase 2 clinical trial. Climb maintains that its payment obligations are limited to products that would infringe patents included in the transferred assets or filed within nine months of the agreement’s closing, which it claims it did not receive. The company is seeking the court’s intervention to clarify its obligations and resolve the ongoing dispute.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL9hWHb3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALMS","BK4539","BK4007","CLYM"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":62,"code":"91000000","status":"200"}]}}